Summary

The global in vitro diagnostics market was valued at $71,496.16 million in 2020, and is projected to reach $106,914.16 million by 2030 registering a CAGR of 4.08% from 2021 to 2030.
In vitro diagnostics (IVD) are defined as reagents, instruments, software and services that are used to examine specimens such as blood, urine, stool, tissues, and other human body fluids, to detect diseases, conditions, and infections. The tests can be performed in stand-alone laboratory, hospital-based laboratory, and point-ofcare centers. Some significant technologies incorporated in in vitro diagnostics include polymerase chain reaction (PCR), microarray techniques, sequencing technology, and mass spectrometry, which are used for test sample preparation.
Moreover, other techniques that are used to perform in vitro diagnosis involve clinical chemistry, tissue diagnostics, immunodiagnostics, hematology, and others. For instance, in clinical chemistry various tests are performed in laboratory such as liver panel test, lipid profile, thyroid function test, and others. Furthermore, a thyroid function test is performed by collecting blood from a patient, which is then tested to check the level of thyroid stimulating hormone (TSH) in blood.
Similarly, others such as polymerase chain reaction (PCR) are used to detect the presence of infectious diseases such as HIV, hepatitis, and others. In addition, constant innovations related to IVD products, service designs, and technology have encouraged doctors and researchers to shift their focus from traditional diagnostic methods to personalized medicines.
For instance, some products that are used to perform various in vitro diagnostic tests using various technologies involve real time PCR detection systems, immunoassay systems, and others. The major factor that contributes to the growth of the in vitro diagnostic market include surge in number of in vitro diagnostic tests, which is attributable to rise in incidences of chronic and infectious diseases. Furthermore, growth in geriatric population, which is prone to immunological disorders is another major factor that boosts the growth of the market. Moreover, rise in use of personalized medicines in treatment of various chronic diseases such as cancer also fuels the growth of the market.
In addition, increase in technological advancements associated with in vitro diagnostic products, technologies, and software & services boosts the market growth. However, stringent government regulations and unfavorable reimbursement policies are anticipated to restrict the growth of the in vitro diagnostics market. On the contrary, high growth rate exhibited by developing economies present lucrative opportunities for key players in the in vitro diagnostics market during the forecast period.
The report segments the market on the basis of product & service, technique, application, end user, and region. On the basis of product & service, the market is classified into reagents, instruments, and services & software. On the basis of technique, it is categorized into immunodiagnostics, hematology, molecular diagnostics, tissue diagnostics, clinical chemistry, and others. In addition, the immunodiagnostics segment is further divided into types such as enzyme-linked immunosorbent assay (ELISA), rapid tests, enzyme-linked immunospot (ELISPOT), radioimmunoassay (RIA), and western blot. Moreover, the ELISA segment is further divided into chemiluminescence immunoassay (CLIA), fluorescence immunoassay (FIA), and colorimetric immunoassay (CI).
Similarly, the molecular diagnostics segment is divided into polymerize chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), hybridization, DNA diagnostics, microarray, and others. The clinical chemistry segment is also further divided basic metabolic panel, liver panel, lipid profile, thyroid function panel, electrolyte panel, specialty chemicals, and others. On the basis of application, the market is classified into infectious diseases, cancer, cardiac diseases, immune system disorders, nephrological diseases, gastrointestinal diseases, and others.
On the basis of end user, it is categorized into standalone laboratories, hospitals, academics & medical schools, point-of-care, and others. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Key players profiled in the report include Abbott Laboratories, Becton, Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation (Beckman Coulter, Inc.), F. Hoffmann-La Roche AG, Siemens AG, QIAGEN N.V., Sysmex Corporation, and Thermo Fisher Scientific, Inc
KEY BENEFITS FOR STAKEHOLDERS
This report provides an extensive analysis of the current and emerging market trends and dynamics in the global photomedicine market to identify the prevailing opportunities.
This study presents the competitive landscape of the global market to predict the competitive environment across geographies.
Comprehensive analysis of factors that drive and restrict the market growth is provided.
Region- & country-wise analysis is provided to understand the market trends and dynamics.

ページTOPに戻る

Table of Contents

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES
4.1 Overview
4.1.1 Market size and forecast
4.2 Reagents
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Instruments
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Software And Services
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
CHAPTER 5: IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
5.1 Overview
5.1.1 Market size and forecast
5.2 Immunodiagnostics
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Hematology
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Molecular Diagnostics
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.5 Tissue Diagnostics
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market analysis by country
5.6 Clinical Chemistry
5.6.1 Key market trends, growth factors and opportunities
5.6.2 Market size and forecast, by region
5.6.3 Market analysis by country
5.7 Others
5.7.1 Key market trends, growth factors and opportunities
5.7.2 Market size and forecast, by region
5.7.3 Market analysis by country
CHAPTER 6: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION
6.1 Overview
6.1.1 Market size and forecast
6.2 Infectious Diseases
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Cancer
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Cardiac Diseases
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
6.5 Immune System Disorders
6.5.1 Key market trends, growth factors and opportunities
6.5.2 Market size and forecast, by region
6.5.3 Market analysis by country
6.6 Nephrological Diseases
6.6.1 Key market trends, growth factors and opportunities
6.6.2 Market size and forecast, by region
6.6.3 Market analysis by country
6.7 Gastrointestinal Diseases
6.7.1 Key market trends, growth factors and opportunities
6.7.2 Market size and forecast, by region
6.7.3 Market analysis by country
6.8 Others
6.8.1 Key market trends, growth factors and opportunities
6.8.2 Market size and forecast, by region
6.8.3 Market analysis by country
CHAPTER 7: IN VITRO DIAGNOSTICS MARKET, BY END USER
7.1 Overview
7.1.1 Market size and forecast
7.2 Standalone Laboratories
7.2.1 Key market trends, growth factors and opportunities
7.2.2 Market size and forecast, by region
7.2.3 Market analysis by country
7.3 Hospitals
7.3.1 Key market trends, growth factors and opportunities
7.3.2 Market size and forecast, by region
7.3.3 Market analysis by country
7.4 Academic And Medical Schools
7.4.1 Key market trends, growth factors and opportunities
7.4.2 Market size and forecast, by region
7.4.3 Market analysis by country
7.5 Point Of Care
7.5.1 Key market trends, growth factors and opportunities
7.5.2 Market size and forecast, by region
7.5.3 Market analysis by country
7.6 Others
7.6.1 Key market trends, growth factors and opportunities
7.6.2 Market size and forecast, by region
7.6.3 Market analysis by country
CHAPTER 8: IN VITRO DIAGNOSTICS MARKET, BY REGION
8.1 Overview
8.1.1 Market size and forecast
8.2 North America
8.2.1 Key trends and opportunities
8.2.2 North America Market size and forecast, by Product And Services
8.2.3 North America Market size and forecast, by Technique
8.2.4 North America Market size and forecast, by Application
8.2.5 North America Market size and forecast, by End User
8.2.6 North America Market size and forecast, by country
8.2.6.1 U.S.
8.2.6.1.1 Market size and forecast, by Product And Services
8.2.6.1.2 Market size and forecast, by Technique
8.2.6.1.3 Market size and forecast, by Application
8.2.6.1.4 Market size and forecast, by End User
8.2.6.2 Canada
8.2.6.2.1 Market size and forecast, by Product And Services
8.2.6.2.2 Market size and forecast, by Technique
8.2.6.2.3 Market size and forecast, by Application
8.2.6.2.4 Market size and forecast, by End User
8.2.6.3 Mexico
8.2.6.3.1 Market size and forecast, by Product And Services
8.2.6.3.2 Market size and forecast, by Technique
8.2.6.3.3 Market size and forecast, by Application
8.2.6.3.4 Market size and forecast, by End User
8.3 Europe
8.3.1 Key trends and opportunities
8.3.2 Europe Market size and forecast, by Product And Services
8.3.3 Europe Market size and forecast, by Technique
8.3.4 Europe Market size and forecast, by Application
8.3.5 Europe Market size and forecast, by End User
8.3.6 Europe Market size and forecast, by country
8.3.6.1 Germany
8.3.6.1.1 Market size and forecast, by Product And Services
8.3.6.1.2 Market size and forecast, by Technique
8.3.6.1.3 Market size and forecast, by Application
8.3.6.1.4 Market size and forecast, by End User
8.3.6.2 France
8.3.6.2.1 Market size and forecast, by Product And Services
8.3.6.2.2 Market size and forecast, by Technique
8.3.6.2.3 Market size and forecast, by Application
8.3.6.2.4 Market size and forecast, by End User
8.3.6.3 United Kingdom
8.3.6.3.1 Market size and forecast, by Product And Services
8.3.6.3.2 Market size and forecast, by Technique
8.3.6.3.3 Market size and forecast, by Application
8.3.6.3.4 Market size and forecast, by End User
8.3.6.4 Italy
8.3.6.4.1 Market size and forecast, by Product And Services
8.3.6.4.2 Market size and forecast, by Technique
8.3.6.4.3 Market size and forecast, by Application
8.3.6.4.4 Market size and forecast, by End User
8.3.6.5 Spain
8.3.6.5.1 Market size and forecast, by Product And Services
8.3.6.5.2 Market size and forecast, by Technique
8.3.6.5.3 Market size and forecast, by Application
8.3.6.5.4 Market size and forecast, by End User
8.3.6.6 Rest of Europe
8.3.6.6.1 Market size and forecast, by Product And Services
8.3.6.6.2 Market size and forecast, by Technique
8.3.6.6.3 Market size and forecast, by Application
8.3.6.6.4 Market size and forecast, by End User
8.4 Asia-Pacific
8.4.1 Key trends and opportunities
8.4.2 Asia-Pacific Market size and forecast, by Product And Services
8.4.3 Asia-Pacific Market size and forecast, by Technique
8.4.4 Asia-Pacific Market size and forecast, by Application
8.4.5 Asia-Pacific Market size and forecast, by End User
8.4.6 Asia-Pacific Market size and forecast, by country
8.4.6.1 China
8.4.6.1.1 Market size and forecast, by Product And Services
8.4.6.1.2 Market size and forecast, by Technique
8.4.6.1.3 Market size and forecast, by Application
8.4.6.1.4 Market size and forecast, by End User
8.4.6.2 Japan
8.4.6.2.1 Market size and forecast, by Product And Services
8.4.6.2.2 Market size and forecast, by Technique
8.4.6.2.3 Market size and forecast, by Application
8.4.6.2.4 Market size and forecast, by End User
8.4.6.3 Australia
8.4.6.3.1 Market size and forecast, by Product And Services
8.4.6.3.2 Market size and forecast, by Technique
8.4.6.3.3 Market size and forecast, by Application
8.4.6.3.4 Market size and forecast, by End User
8.4.6.4 India
8.4.6.4.1 Market size and forecast, by Product And Services
8.4.6.4.2 Market size and forecast, by Technique
8.4.6.4.3 Market size and forecast, by Application
8.4.6.4.4 Market size and forecast, by End User
8.4.6.5 South Korea
8.4.6.5.1 Market size and forecast, by Product And Services
8.4.6.5.2 Market size and forecast, by Technique
8.4.6.5.3 Market size and forecast, by Application
8.4.6.5.4 Market size and forecast, by End User
8.4.6.6 Rest of Asia-Pacific
8.4.6.6.1 Market size and forecast, by Product And Services
8.4.6.6.2 Market size and forecast, by Technique
8.4.6.6.3 Market size and forecast, by Application
8.4.6.6.4 Market size and forecast, by End User
8.5 LAMEA
8.5.1 Key trends and opportunities
8.5.2 LAMEA Market size and forecast, by Product And Services
8.5.3 LAMEA Market size and forecast, by Technique
8.5.4 LAMEA Market size and forecast, by Application
8.5.5 LAMEA Market size and forecast, by End User
8.5.6 LAMEA Market size and forecast, by country
8.5.6.1 Brazil
8.5.6.1.1 Market size and forecast, by Product And Services
8.5.6.1.2 Market size and forecast, by Technique
8.5.6.1.3 Market size and forecast, by Application
8.5.6.1.4 Market size and forecast, by End User
8.5.6.2 Saudi Arabia
8.5.6.2.1 Market size and forecast, by Product And Services
8.5.6.2.2 Market size and forecast, by Technique
8.5.6.2.3 Market size and forecast, by Application
8.5.6.2.4 Market size and forecast, by End User
8.5.6.3 South Africa
8.5.6.3.1 Market size and forecast, by Product And Services
8.5.6.3.2 Market size and forecast, by Technique
8.5.6.3.3 Market size and forecast, by Application
8.5.6.3.4 Market size and forecast, by End User
8.5.6.4 Rest of LAMEA
8.5.6.4.1 Market size and forecast, by Product And Services
8.5.6.4.2 Market size and forecast, by Technique
8.5.6.4.3 Market size and forecast, by Application
8.5.6.4.4 Market size and forecast, by End User
CHAPTER 9: COMPANY LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Key developments
CHAPTER 10: COMPANY PROFILES
10.1 Abbott Laboratories
10.1.1 Company overview
10.1.2 Company snapshot
10.1.3 Operating business segments
10.1.4 Product portfolio
10.1.5 Business performance
10.1.6 Key strategic moves and developments
10.2 Becton, Dickinson and Company
10.2.1 Company overview
10.2.2 Company snapshot
10.2.3 Operating business segments
10.2.4 Product portfolio
10.2.5 Business performance
10.2.6 Key strategic moves and developments
10.3 bioMérieux SA
10.3.1 Company overview
10.3.2 Company snapshot
10.3.3 Operating business segments
10.3.4 Product portfolio
10.3.5 Business performance
10.3.6 Key strategic moves and developments
10.4 Bio-Rad Laboratories, Inc.
10.4.1 Company overview
10.4.2 Company snapshot
10.4.3 Operating business segments
10.4.4 Product portfolio
10.4.5 Business performance
10.4.6 Key strategic moves and developments
10.5 Danaher Corporation (Beckman Coulter, Inc.)
10.5.1 Company overview
10.5.2 Company snapshot
10.5.3 Operating business segments
10.5.4 Product portfolio
10.5.5 Business performance
10.5.6 Key strategic moves and developments
10.6 F. Hoffmann-La Roche AG
10.6.1 Company overview
10.6.2 Company snapshot
10.6.3 Operating business segments
10.6.4 Product portfolio
10.6.5 Business performance
10.6.6 Key strategic moves and developments
10.7 Siemens AG
10.7.1 Company overview
10.7.2 Company snapshot
10.7.3 Operating business segments
10.7.4 Product portfolio
10.7.5 Business performance
10.7.6 Key strategic moves and developments
10.8 QIAGEN N.V.
10.8.1 Company overview
10.8.2 Company snapshot
10.8.3 Operating business segments
10.8.4 Product portfolio
10.8.5 Business performance
10.8.6 Key strategic moves and developments
10.9 Sysmex Corporation
10.9.1 Company overview
10.9.2 Company snapshot
10.9.3 Operating business segments
10.9.4 Product portfolio
10.9.5 Business performance
10.9.6 Key strategic moves and developments
10.10 Thermo Fisher Scientific, Inc.
10.10.1 Company overview
10.10.2 Company snapshot
10.10.3 Operating business segments
10.10.4 Product portfolio
10.10.5 Business performance
10.10.6 Key strategic moves and developments


LIST OF TABLES
TABLE 1. GLOBAL IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2020-2030,($MILLION)
TABLE 2. IN VITRO DIAGNOSTICS MARKET REVENUE, FOR REAGENTS, BY REGION , 2020-2030,($MILLION)
TABLE 3. IN VITRO DIAGNOSTICS MARKET REAGENTS BY COUNTRY, 2020-2030,($MILLION)
TABLE 4. IN VITRO DIAGNOSTICS MARKET REVENUE, FOR INSTRUMENTS, BY REGION , 2020-2030,($MILLION)
TABLE 5. IN VITRO DIAGNOSTICS MARKET INSTRUMENTS BY COUNTRY, 2020-2030,($MILLION)
TABLE 6. IN VITRO DIAGNOSTICS MARKET REVENUE, FOR SOFTWARE AND SERVICES, BY REGION , 2020-2030,($MILLION)
TABLE 7. IN VITRO DIAGNOSTICS MARKET SOFTWARE AND SERVICES BY COUNTRY, 2020-2030,($MILLION)
TABLE 8. GLOBAL IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2020-2030,($MILLION)
TABLE 9. IN VITRO DIAGNOSTICS MARKET REVENUE, FOR IMMUNODIAGNOSTICS, BY REGION , 2020-2030,($MILLION)
TABLE 10. IN VITRO DIAGNOSTICS MARKET IMMUNODIAGNOSTICS BY COUNTRY, 2020-2030,($MILLION)
TABLE 11. IN VITRO DIAGNOSTICS MARKET REVENUE, FOR HEMATOLOGY, BY REGION , 2020-2030,($MILLION)
TABLE 12. IN VITRO DIAGNOSTICS MARKET HEMATOLOGY BY COUNTRY, 2020-2030,($MILLION)
TABLE 13. IN VITRO DIAGNOSTICS MARKET REVENUE, FOR MOLECULAR DIAGNOSTICS, BY REGION , 2020-2030,($MILLION)
TABLE 14. IN VITRO DIAGNOSTICS MARKET MOLECULAR DIAGNOSTICS BY COUNTRY, 2020-2030,($MILLION)
TABLE 15. IN VITRO DIAGNOSTICS MARKET REVENUE, FOR TISSUE DIAGNOSTICS, BY REGION , 2020-2030,($MILLION)
TABLE 16. IN VITRO DIAGNOSTICS MARKET TISSUE DIAGNOSTICS BY COUNTRY, 2020-2030,($MILLION)
TABLE 17. IN VITRO DIAGNOSTICS MARKET REVENUE, FOR CLINICAL CHEMISTRY, BY REGION , 2020-2030,($MILLION)
TABLE 18. IN VITRO DIAGNOSTICS MARKET CLINICAL CHEMISTRY BY COUNTRY, 2020-2030,($MILLION)
TABLE 19. IN VITRO DIAGNOSTICS MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)
TABLE 20. IN VITRO DIAGNOSTICS MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)
TABLE 21. GLOBAL IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 22. IN VITRO DIAGNOSTICS MARKET REVENUE, FOR INFECTIOUS DISEASES, BY REGION , 2020-2030,($MILLION)
TABLE 23. IN VITRO DIAGNOSTICS MARKET INFECTIOUS DISEASES BY COUNTRY, 2020-2030,($MILLION)
TABLE 24. IN VITRO DIAGNOSTICS MARKET REVENUE, FOR CANCER, BY REGION , 2020-2030,($MILLION)
TABLE 25. IN VITRO DIAGNOSTICS MARKET CANCER BY COUNTRY, 2020-2030,($MILLION)
TABLE 26. IN VITRO DIAGNOSTICS MARKET REVENUE, FOR CARDIAC DISEASES, BY REGION , 2020-2030,($MILLION)
TABLE 27. IN VITRO DIAGNOSTICS MARKET CARDIAC DISEASES BY COUNTRY, 2020-2030,($MILLION)
TABLE 28. IN VITRO DIAGNOSTICS MARKET REVENUE, FOR IMMUNE SYSTEM DISORDERS, BY REGION , 2020-2030,($MILLION)
TABLE 29. IN VITRO DIAGNOSTICS MARKET IMMUNE SYSTEM DISORDERS BY COUNTRY, 2020-2030,($MILLION)
TABLE 30. IN VITRO DIAGNOSTICS MARKET REVENUE, FOR NEPHROLOGICAL DISEASES, BY REGION , 2020-2030,($MILLION)
TABLE 31. IN VITRO DIAGNOSTICS MARKET NEPHROLOGICAL DISEASES BY COUNTRY, 2020-2030,($MILLION)
TABLE 32. IN VITRO DIAGNOSTICS MARKET REVENUE, FOR GASTROINTESTINAL DISEASES, BY REGION , 2020-2030,($MILLION)
TABLE 33. IN VITRO DIAGNOSTICS MARKET GASTROINTESTINAL DISEASES BY COUNTRY, 2020-2030,($MILLION)
TABLE 34. IN VITRO DIAGNOSTICS MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)
TABLE 35. IN VITRO DIAGNOSTICS MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)
TABLE 36. GLOBAL IN VITRO DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 37. IN VITRO DIAGNOSTICS MARKET REVENUE, FOR STANDALONE LABORATORIES, BY REGION , 2020-2030,($MILLION)
TABLE 38. IN VITRO DIAGNOSTICS MARKET STANDALONE LABORATORIES BY COUNTRY, 2020-2030,($MILLION)
TABLE 39. IN VITRO DIAGNOSTICS MARKET REVENUE, FOR HOSPITALS, BY REGION , 2020-2030,($MILLION)
TABLE 40. IN VITRO DIAGNOSTICS MARKET HOSPITALS BY COUNTRY, 2020-2030,($MILLION)
TABLE 41. IN VITRO DIAGNOSTICS MARKET REVENUE, FOR ACADEMIC AND MEDICAL SCHOOLS, BY REGION , 2020-2030,($MILLION)
TABLE 42. IN VITRO DIAGNOSTICS MARKET ACADEMIC AND MEDICAL SCHOOLS BY COUNTRY, 2020-2030,($MILLION)
TABLE 43. IN VITRO DIAGNOSTICS MARKET REVENUE, FOR POINT OF CARE, BY REGION , 2020-2030,($MILLION)
TABLE 44. IN VITRO DIAGNOSTICS MARKET POINT OF CARE BY COUNTRY, 2020-2030,($MILLION)
TABLE 45. IN VITRO DIAGNOSTICS MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)
TABLE 46. IN VITRO DIAGNOSTICS MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)
TABLE 47. IN VITRO DIAGNOSTICS MARKET, BY REGION, 2020-2030,($MILLION)
TABLE 48. NORTH AMERICA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2020-2030,($MILLION)
TABLE 49. NORTH AMERICA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2020-2030,($MILLION)
TABLE 50. NORTH AMERICA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 51. NORTH AMERICA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 52. NORTH AMERICA IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 53. U.S. IN VITRO DIAGNOSTICS MARKET BY PRODUCT AND SERVICES 2020-2030,($MILLION)
TABLE 54. U.S. IN VITRO DIAGNOSTICS MARKET BY TECHNIQUE 2020-2030,($MILLION)
TABLE 55. U.S. IN VITRO DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 56. U.S. IN VITRO DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 57. CANADA IN VITRO DIAGNOSTICS MARKET BY PRODUCT AND SERVICES 2020-2030,($MILLION)
TABLE 58. CANADA IN VITRO DIAGNOSTICS MARKET BY TECHNIQUE 2020-2030,($MILLION)
TABLE 59. CANADA IN VITRO DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 60. CANADA IN VITRO DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 61. MEXICO IN VITRO DIAGNOSTICS MARKET BY PRODUCT AND SERVICES 2020-2030,($MILLION)
TABLE 62. MEXICO IN VITRO DIAGNOSTICS MARKET BY TECHNIQUE 2020-2030,($MILLION)
TABLE 63. MEXICO IN VITRO DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 64. MEXICO IN VITRO DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 65. EUROPE IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2020-2030,($MILLION)
TABLE 66. EUROPE IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2020-2030,($MILLION)
TABLE 67. EUROPE IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 68. EUROPE IN VITRO DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 69. EUROPE IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 70. GERMANY IN VITRO DIAGNOSTICS MARKET BY PRODUCT AND SERVICES 2020-2030,($MILLION)
TABLE 71. GERMANY IN VITRO DIAGNOSTICS MARKET BY TECHNIQUE 2020-2030,($MILLION)
TABLE 72. GERMANY IN VITRO DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 73. GERMANY IN VITRO DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 74. FRANCE IN VITRO DIAGNOSTICS MARKET BY PRODUCT AND SERVICES 2020-2030,($MILLION)
TABLE 75. FRANCE IN VITRO DIAGNOSTICS MARKET BY TECHNIQUE 2020-2030,($MILLION)
TABLE 76. FRANCE IN VITRO DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 77. FRANCE IN VITRO DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 78. UNITED KINGDOM IN VITRO DIAGNOSTICS MARKET BY PRODUCT AND SERVICES 2020-2030,($MILLION)
TABLE 79. UNITED KINGDOM IN VITRO DIAGNOSTICS MARKET BY TECHNIQUE 2020-2030,($MILLION)
TABLE 80. UNITED KINGDOM IN VITRO DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 81. UNITED KINGDOM IN VITRO DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 82. ITALY IN VITRO DIAGNOSTICS MARKET BY PRODUCT AND SERVICES 2020-2030,($MILLION)
TABLE 83. ITALY IN VITRO DIAGNOSTICS MARKET BY TECHNIQUE 2020-2030,($MILLION)
TABLE 84. ITALY IN VITRO DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 85. ITALY IN VITRO DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 86. SPAIN IN VITRO DIAGNOSTICS MARKET BY PRODUCT AND SERVICES 2020-2030,($MILLION)
TABLE 87. SPAIN IN VITRO DIAGNOSTICS MARKET BY TECHNIQUE 2020-2030,($MILLION)
TABLE 88. SPAIN IN VITRO DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 89. SPAIN IN VITRO DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 90. REST OF EUROPE IN VITRO DIAGNOSTICS MARKET BY PRODUCT AND SERVICES 2020-2030,($MILLION)
TABLE 91. REST OF EUROPE IN VITRO DIAGNOSTICS MARKET BY TECHNIQUE 2020-2030,($MILLION)
TABLE 92. REST OF EUROPE IN VITRO DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 93. REST OF EUROPE IN VITRO DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 94. ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2020-2030,($MILLION)
TABLE 95. ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2020-2030,($MILLION)
TABLE 96. ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 97. ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 98. ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 99. CHINA IN VITRO DIAGNOSTICS MARKET BY PRODUCT AND SERVICES 2020-2030,($MILLION)
TABLE 100. CHINA IN VITRO DIAGNOSTICS MARKET BY TECHNIQUE 2020-2030,($MILLION)
TABLE 101. CHINA IN VITRO DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 102. CHINA IN VITRO DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 103. JAPAN IN VITRO DIAGNOSTICS MARKET BY PRODUCT AND SERVICES 2020-2030,($MILLION)
TABLE 104. JAPAN IN VITRO DIAGNOSTICS MARKET BY TECHNIQUE 2020-2030,($MILLION)
TABLE 105. JAPAN IN VITRO DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 106. JAPAN IN VITRO DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 107. AUSTRALIA IN VITRO DIAGNOSTICS MARKET BY PRODUCT AND SERVICES 2020-2030,($MILLION)
TABLE 108. AUSTRALIA IN VITRO DIAGNOSTICS MARKET BY TECHNIQUE 2020-2030,($MILLION)
TABLE 109. AUSTRALIA IN VITRO DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 110. AUSTRALIA IN VITRO DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 111. INDIA IN VITRO DIAGNOSTICS MARKET BY PRODUCT AND SERVICES 2020-2030,($MILLION)
TABLE 112. INDIA IN VITRO DIAGNOSTICS MARKET BY TECHNIQUE 2020-2030,($MILLION)
TABLE 113. INDIA IN VITRO DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 114. INDIA IN VITRO DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 115. SOUTH KOREA IN VITRO DIAGNOSTICS MARKET BY PRODUCT AND SERVICES 2020-2030,($MILLION)
TABLE 116. SOUTH KOREA IN VITRO DIAGNOSTICS MARKET BY TECHNIQUE 2020-2030,($MILLION)
TABLE 117. SOUTH KOREA IN VITRO DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 118. SOUTH KOREA IN VITRO DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 119. REST OF ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET BY PRODUCT AND SERVICES 2020-2030,($MILLION)
TABLE 120. REST OF ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET BY TECHNIQUE 2020-2030,($MILLION)
TABLE 121. REST OF ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 122. REST OF ASIA-PACIFIC IN VITRO DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 123. LAMEA IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES, 2020-2030,($MILLION)
TABLE 124. LAMEA IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2020-2030,($MILLION)
TABLE 125. LAMEA IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2020-2030,($MILLION)
TABLE 126. LAMEA IN VITRO DIAGNOSTICS MARKET, BY END USER, 2020-2030,($MILLION)
TABLE 127. LAMEA IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 128. BRAZIL IN VITRO DIAGNOSTICS MARKET BY PRODUCT AND SERVICES 2020-2030,($MILLION)
TABLE 129. BRAZIL IN VITRO DIAGNOSTICS MARKET BY TECHNIQUE 2020-2030,($MILLION)
TABLE 130. BRAZIL IN VITRO DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 131. BRAZIL IN VITRO DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 132. SAUDI ARABIA IN VITRO DIAGNOSTICS MARKET BY PRODUCT AND SERVICES 2020-2030,($MILLION)
TABLE 133. SAUDI ARABIA IN VITRO DIAGNOSTICS MARKET BY TECHNIQUE 2020-2030,($MILLION)
TABLE 134. SAUDI ARABIA IN VITRO DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 135. SAUDI ARABIA IN VITRO DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 136. SOUTH AFRICA IN VITRO DIAGNOSTICS MARKET BY PRODUCT AND SERVICES 2020-2030,($MILLION)
TABLE 137. SOUTH AFRICA IN VITRO DIAGNOSTICS MARKET BY TECHNIQUE 2020-2030,($MILLION)
TABLE 138. SOUTH AFRICA IN VITRO DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 139. SOUTH AFRICA IN VITRO DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 140. REST OF LAMEA IN VITRO DIAGNOSTICS MARKET BY PRODUCT AND SERVICES 2020-2030,($MILLION)
TABLE 141. REST OF LAMEA IN VITRO DIAGNOSTICS MARKET BY TECHNIQUE 2020-2030,($MILLION)
TABLE 142. REST OF LAMEA IN VITRO DIAGNOSTICS MARKET BY APPLICATION 2020-2030,($MILLION)
TABLE 143. REST OF LAMEA IN VITRO DIAGNOSTICS MARKET BY END USER 2020-2030,($MILLION)
TABLE 144.ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 145.ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 146.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 147.ABBOTT LABORATORIES: NET SALES,
TABLE 148.ABBOTT LABORATORIES: KEY STRATERGIES
TABLE 149.BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
TABLE 150.BECTON, DICKINSON AND COMPANY: OPERATING SEGMENTS
TABLE 151.BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO
TABLE 152.BECTON, DICKINSON AND COMPANY: NET SALES,
TABLE 153.BECTON, DICKINSON AND COMPANY: KEY STRATERGIES
TABLE 154.BIOMÉRIEUX SA: COMPANY SNAPSHOT
TABLE 155.BIOMÉRIEUX SA: OPERATING SEGMENTS
TABLE 156.BIOMÉRIEUX SA: PRODUCT PORTFOLIO
TABLE 157.BIOMÉRIEUX SA: NET SALES,
TABLE 158.BIOMÉRIEUX SA: KEY STRATERGIES
TABLE 159.BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
TABLE 160.BIO-RAD LABORATORIES, INC.: OPERATING SEGMENTS
TABLE 161.BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
TABLE 162.BIO-RAD LABORATORIES, INC.: NET SALES,
TABLE 163.BIO-RAD LABORATORIES, INC.: KEY STRATERGIES
TABLE 164.DANAHER CORPORATION (BECKMAN COULTER, INC.): COMPANY SNAPSHOT
TABLE 165.DANAHER CORPORATION (BECKMAN COULTER, INC.): OPERATING SEGMENTS
TABLE 166.DANAHER CORPORATION (BECKMAN COULTER, INC.): PRODUCT PORTFOLIO
TABLE 167.DANAHER CORPORATION (BECKMAN COULTER, INC.): NET SALES,
TABLE 168.DANAHER CORPORATION (BECKMAN COULTER, INC.): KEY STRATERGIES
TABLE 169.F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
TABLE 170.F. HOFFMANN-LA ROCHE AG: OPERATING SEGMENTS
TABLE 171.F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
TABLE 172.F. HOFFMANN-LA ROCHE AG: NET SALES,
TABLE 173.F. HOFFMANN-LA ROCHE AG: KEY STRATERGIES
TABLE 174.SIEMENS AG: COMPANY SNAPSHOT
TABLE 175.SIEMENS AG: OPERATING SEGMENTS
TABLE 176.SIEMENS AG: PRODUCT PORTFOLIO
TABLE 177.SIEMENS AG: NET SALES,
TABLE 178.SIEMENS AG: KEY STRATERGIES
TABLE 179.QIAGEN N.V.: COMPANY SNAPSHOT
TABLE 180.QIAGEN N.V.: OPERATING SEGMENTS
TABLE 181.QIAGEN N.V.: PRODUCT PORTFOLIO
TABLE 182.QIAGEN N.V.: NET SALES,
TABLE 183.QIAGEN N.V.: KEY STRATERGIES
TABLE 184.SYSMEX CORPORATION: COMPANY SNAPSHOT
TABLE 185.SYSMEX CORPORATION: OPERATING SEGMENTS
TABLE 186.SYSMEX CORPORATION: PRODUCT PORTFOLIO
TABLE 187.SYSMEX CORPORATION: NET SALES,
TABLE 188.SYSMEX CORPORATION: KEY STRATERGIES
TABLE 189.THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
TABLE 190.THERMO FISHER SCIENTIFIC, INC.: OPERATING SEGMENTS
TABLE 191.THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO
TABLE 192.THERMO FISHER SCIENTIFIC, INC.: NET SALES,
TABLE 193.THERMO FISHER SCIENTIFIC, INC.: KEY STRATERGIES


LIST OF FIGURES
FIGURE 1.IN VITRO DIAGNOSTICS MARKET SEGMENTATION
FIGURE 2.IN VITRO DIAGNOSTICS MARKET,2020-2030
FIGURE 3.IN VITRO DIAGNOSTICS MARKET,2020-2030
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.IN VITRO DIAGNOSTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11.IN VITRO DIAGNOSTICS MARKET,BY PRODUCT AND SERVICES,2020(%)
FIGURE 12.COMPARATIVE SHARE ANALYSIS OF REAGENTS IN VITRO DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF INSTRUMENTS IN VITRO DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF SOFTWARE AND SERVICES IN VITRO DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 15.IN VITRO DIAGNOSTICS MARKET,BY TECHNIQUE,2020(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF IMMUNODIAGNOSTICS IN VITRO DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF HEMATOLOGY IN VITRO DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF MOLECULAR DIAGNOSTICS IN VITRO DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF TISSUE DIAGNOSTICS IN VITRO DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF CLINICAL CHEMISTRY IN VITRO DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 21.COMPARATIVE SHARE ANALYSIS OF OTHERS IN VITRO DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 22.IN VITRO DIAGNOSTICS MARKET,BY APPLICATION,2020(%)
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF INFECTIOUS DISEASES IN VITRO DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 24.COMPARATIVE SHARE ANALYSIS OF CANCER IN VITRO DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 25.COMPARATIVE SHARE ANALYSIS OF CARDIAC DISEASES IN VITRO DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 26.COMPARATIVE SHARE ANALYSIS OF IMMUNE SYSTEM DISORDERS IN VITRO DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 27.COMPARATIVE SHARE ANALYSIS OF NEPHROLOGICAL DISEASES IN VITRO DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 28.COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL DISEASES IN VITRO DIAGNOSTICS MARKET,2020-2030(%)
FIGURE 29.COMPARATIVE SHARE ANALYSIS OF OTHERS I